MX363679B - Metodo para diagnosticar cancer. - Google Patents

Metodo para diagnosticar cancer.

Info

Publication number
MX363679B
MX363679B MX2015015015A MX2015015015A MX363679B MX 363679 B MX363679 B MX 363679B MX 2015015015 A MX2015015015 A MX 2015015015A MX 2015015015 A MX2015015015 A MX 2015015015A MX 363679 B MX363679 B MX 363679B
Authority
MX
Mexico
Prior art keywords
glioblastoma
cd95l
expression
sample
positive
Prior art date
Application number
MX2015015015A
Other languages
English (en)
Other versions
MX2015015015A (es
Inventor
Gieffers Christian
Fricke Harald
Sykora Jaromir
Original Assignee
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Ag filed Critical Apogenix Ag
Publication of MX2015015015A publication Critical patent/MX2015015015A/es
Publication of MX363679B publication Critical patent/MX363679B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método in vitro para diagnosticar glioblastoma, caracterizado porque comprende: (a) determinar la expresión de CD95L en una muestra de glioblastoma, y (b) clasificar el glioblastoma de acuerdo con el nivel de expresión de CD95L, en donde el glioblastoma se clasifica por el nivel de expresión de CD95L en un glioblastoma CD95L positivo o un glioblastoma CD95L negativo, en donde el glioblastoma se considera como CD95L positivo si al menos el 5% de las células en la muestra expresan CD95L y/o si se puede detectar CD95L en al menos el 5% del área del tejido tumoral en una muestra de tejido de glioblastoma.
MX2015015015A 2013-04-29 2014-04-29 Metodo para diagnosticar cancer. MX363679B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165784 2013-04-29
PCT/EP2014/058746 WO2014177576A1 (en) 2013-04-29 2014-04-29 Method of diagnosing cancer

Publications (2)

Publication Number Publication Date
MX2015015015A MX2015015015A (es) 2016-07-21
MX363679B true MX363679B (es) 2019-03-29

Family

ID=48190325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015015A MX363679B (es) 2013-04-29 2014-04-29 Metodo para diagnosticar cancer.

Country Status (9)

Country Link
US (1) US20160103132A1 (es)
EP (1) EP2992330B1 (es)
JP (1) JP6556121B2 (es)
CN (1) CN105393121B (es)
AU (1) AU2014261505B2 (es)
BR (1) BR112015027249A2 (es)
CA (1) CA2910332A1 (es)
MX (1) MX363679B (es)
WO (1) WO2014177576A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2877989C (en) 2012-07-18 2021-05-25 Apogenix Gmbh Shortened cd95-fc variants
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
EP3076179A1 (en) * 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
WO2017009429A1 (en) * 2015-07-14 2017-01-19 Apogenix Ag Method of predicting the responsiveness of a cancer disease to treatment
US20250002596A1 (en) * 2021-12-01 2025-01-02 Institut National de la Santé et de la Recherche Médicale Neutralizing anti-cd95l monoclonal antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779215B2 (en) * 1999-07-16 2005-01-13 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
WO2003008649A1 (en) * 2001-07-20 2003-01-30 Board Of Regents, The University Of Texas System Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
US20030078228A1 (en) * 2001-09-24 2003-04-24 Taylor Doris A. Fas Ligand
US7262277B2 (en) * 2002-03-21 2007-08-28 Eli Lilly And Company Antagonistic anti-hFAS ligand human antibodies and fragments thereof
US8324188B2 (en) * 2006-11-10 2012-12-04 Vladimir Khazak Combinations of ET-18-O-CH3and anti-cancer agents for the treatment of cancer
DK2101877T3 (da) * 2006-12-28 2013-09-23 Deutsches Krebsforsch Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo
US20090234202A1 (en) * 2008-03-05 2009-09-17 Goix Philippe J Method and compositions for highly sensitive detection of molecules
WO2011010156A1 (en) * 2009-07-21 2011-01-27 Queen Mary & Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
CA2877989C (en) * 2012-07-18 2021-05-25 Apogenix Gmbh Shortened cd95-fc variants

Also Published As

Publication number Publication date
CN105393121B (zh) 2018-04-24
JP2016524694A (ja) 2016-08-18
CA2910332A1 (en) 2014-11-06
AU2014261505B2 (en) 2019-04-18
MX2015015015A (es) 2016-07-21
WO2014177576A1 (en) 2014-11-06
EP2992330B1 (en) 2018-04-18
JP6556121B2 (ja) 2019-08-07
BR112015027249A2 (pt) 2017-09-26
EP2992330A1 (en) 2016-03-09
US20160103132A1 (en) 2016-04-14
AU2014261505A1 (en) 2015-11-12
CN105393121A (zh) 2016-03-09

Similar Documents

Publication Publication Date Title
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
IN2015DN00678A (es)
MX383381B (es) Métodos y composiciones para detectar proteínas mal plegadas.
AR095233A1 (es) Métodos y composiciones para el control de malezas
MX373957B (es) Un método in vitro para detectar un biomarcador de cáncer en un sujeto.
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
BR112014025520A2 (pt) método para estimar características de uma formação
CY1118694T1 (el) Μεθοδοι διαχωρισμου σωματιδιων χρησιμοποιωντας μια συσκευη με ενα στοιχειο διαχωρισμου με διακριση μεγεθους που εχει μια επιμηκη αιχμη
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
MX2017012320A (es) Estandares de antigeno prostatico y sus usos.
UY34243A (es) Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
AR092423A1 (es) Metodo de diagnostico y tratamiento del cancer dirigido a las moleculas expresadas en celulas madre cancerosas
MX2015015015A (es) Metodo para diagnosticar cancer.
MX345893B (es) Ensayo para clasificación de compuestos que disminuyen selectivamente el número de células madre de cáncer.
BR112016002709A2 (pt) queratinas como biomarcadores para câncer cervical e sobrevivência
EA201691168A1 (ru) Способы исследования бета-глюкана
MX384485B (es) Deteccion temprana de preeclampsia.
MX2015015023A (es) Metodo para la determinacion de cobre libre.
AR099753A1 (es) Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro
UA116372C2 (uk) Частинки резинату фенілефрину